Start / PharmaTalkRadio / 2025 biotech markets immuno oncology outlook

PharmaTalkRadio

2025 Biotech Markets & Immuno-Oncology Outlook

20 min • 25 juni 2025

Summary:
Mizuho Securities Analyst, Dr Graig Suvannavejh, joined the 2025 Immuno-Oncology 360º Summit to share an outlook on the IO biotech market, high-level thoughts on the IO space, and public IO company case studies to illustrate the market's perception of what's happening in IO.

More specifically:

The current tailwinds working for and headwinds working against investment in biotech
The increasing specialization of investors and lack of generalist investors
The impacts of challenging and/or disappointing readouts after the first wave of checkpoint inhibitors
Where investors are more positive on biotech, and reasons for optimism in coming pipelines

For more information, visit IO360summit.com

Senaste avsnitt

Stanford's Dr Crystal Mackall on the Evolution of and Future Directions in Cell Therapy

14 augusti | 29 min

De-Risking Clinical Operations by Taking a Scaffolding Approach to Outsourcing

12 augusti | 28 min

Balancing Between Concentration and Volume when Developing Patient-Centric Biologics

12 augusti | 28 min

Directors' Talk DPHARM 2025 - AI Sessions; Part III

25 juli | 6 min

Innovations in Manufacturing to Make CAR-T More Accessible and Affordable

25 juli | 20 min

Podcastbild

00:00 -00:00

Podcastbild

00:00 -00:00